小鼠IgG -同型对照(ab37355)
概述
-
产品名称
小鼠IgG -同型对照
参阅全部 Mouse 亚类对照 -
特异性
This antibody has been selected as an isotype control as it has no known specificity.
-
经测试应用
适用于: ELISA, Flow Cyt, IHCmore details -
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
pH: 8.20
Constituent: 100% Borate buffered saline -
Concentration information loading...
-
纯度
Affinity purified -
纯化说明
Purified from normal mouse serum. -
克隆
多克隆 -
同种型
IgG -
研究领域
-
别名
- Mouse Isotype Control
相关产品
-
Compatible Secondaries
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab37355于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
Flow Cyt |
Use at an assay dependent concentration.
ab37355 - Mouse polyclonal IgG, is suitable for use as an isotype control with this antibody.
|
|
IHC |
Use at an assay dependent concentration.
|
说明 |
---|
ELISA
Use at an assay dependent concentration. |
Flow Cyt
Use at an assay dependent concentration. ab37355 - Mouse polyclonal IgG, is suitable for use as an isotype control with this antibody.
|
IHC
Use at an assay dependent concentration. |
图片
实验方案
数据表及文件
-
SDS download
-
Datasheet download
文献 (65)
ab37355 被引用在 65 文献中.
- Nataraj NB et al. Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors. Cell Rep 38:110418 (2022). PubMed: 35196484
- Wang L et al. High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy. Int J Oncol 60:N/A (2022). PubMed: 35211760
- Melendez E et al. Natural killer cells act as an extrinsic barrier for in vivo reprogramming. Development 149:N/A (2022). PubMed: 35420133
- Chen L et al. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. J Exp Clin Cancer Res 41:194 (2022). PubMed: 35659274
- Zhu C et al. An intranasal ASO therapeutic targeting SARS-CoV-2. Nat Commun 13:4503 (2022). PubMed: 35922434